Confirmed Speakers

The Organising Committee is pleased to announce that the following speakers have confirmed their attendance to the 11th Symposium on Pharmaceutical Profiling in Drug Discovery and Development.


Dr. Annabelle Biscans, AstraZeneca R&D Dr. Annabelle Biscans is Associate Principal Scientist in the AstraZeneca R&D Oligonucleotide Chemistry Team. After completing her PhD at the University of Montpellier, Dr. Biscans joined Anastasia Khvorova’s lab at the University of Massachusetts Medical School, before being recruited to AstraZeneca R&D in 2020.

Dr. Biscans research is focused on designing and engineering conjugated fully stabilized siRNAs to enhance their delivery into extrahepatic tissues. During her career she has made major contributions to the development of novel chemical platforms for enhancing the delivery and uptake of siRNA therapeutics.


Samir El AndaluossiSamir EL Andaloussi is Professor of Biomolecular Medicine and Advanced Therapies at Karolinska Institutet. After receiving his PhD in 2008 at Stockholm University and a postdoctoral stint at Karolinska Institutet, Professor EL Andaloussi moved to University of Oxford to work with extracellular vesicles (EVs), before returning to Karolinska Institutet in 2013.

The Samir EL Andaloussi research group, among many focus areas, develop innovative drug delivery technologies that are able to carry protein and/or gene therapies to the target tissues safely and efficiently. The group has developed a promising technology based on reprogramming exosomes, which are vesicles that are naturally used by cells to communicate, to carry therapeutic proteins and nucleic acids.

Adj. Professor Ola Engkvist, Chalmers University of Technology, AstraZeneca R&D (SE)

Ola EngkvistOla Engkvist is Adjunct Professor in AI and Machine Learning Based Drug Design at Chalmers University of Technology and Head of Molecular AI at AstraZeneca R&D. Ola Engkvist completed his PhD in Computational Chemistry at the University of Lund and postdoc research at the University of Cambridge and the Czech Academy of Sciences.

Ola Engkvist joined AstraZeneca in 2004, currently leading the Discovery Sciences Computational Chemistry team within BioPharmaceuticals R&D, providing computational solutions for drug discovery. A focus area in Ola Engkvist’s work is using artificial intelligence and machine learning in drug discovery anf collaborating with external experts to advance innovation in drug design and synthesis.

Ass. Prof. Maria Kjellsson, Uppsala University (SE)

Maria KjellssonMaria Kjellsson is Associate Professor at Uppsala University’s Department of Pharmacy, co-leading the Pharmacometric diabetes research group together with prof. Mats Karlsson. Maria Kjellsson received her PhD at Uppsala University, joined Novartis as a visiting scientist in 2008 before her return to Uppsala University.

Maria Kjellsson’s research is focused on using mixed-effects models to investigate, describe and quantify various time-varying aspects of diabetes, such as disease progression and treatment effects. The models developed span from describing pre-clinical provocations experiments, clinical provocations and HbA1c studies all the way to models describing cardio-vascular disease (CVD) and kidney disease using registry data. Maria Kjellsson is also involved in the IMI project, DDMoRe and collaborates with National Diabetes Registry and University of Eastern Finland.


PROF. PÄR MATSSONPär Matsson is Professor of Pharmacokinetics at the Sahlgrenska Academy, University of Gothenburg, in the field of drug disposition modeling. After completeing his PhD and continuing his research at Uppsala University, Professor Matsson was recruited to the University of Gothenburg in 2019.

The Pär Matsson research group study how drug molecules are absorbed by the human body, how they distribute to different tissues, and how they are eliminated through metabolism and excretion. Their focus is on the cellular and molecular mechanisms involved, and we study these using a combination of biophysical and cell-based experiments, imaging, and computational modeling and simulation. 


Ola SpjuthOla Spjuth is Professor of Pharmaceutical Bioinformatics at Uppsala University’s Department of Pharmaceutical Biosciences. Professor Ola Spjuth was co-director at the UPPMAX high performance computing center at Uppsala University (2010-2017), and headed the Bioinformatics Compute and Storage facility at Science for Life Laboratory in Sweden (2010-2017).

The research at Lab Ola Spjuth is focused on data-intensive bioinformatics and how automated high-throughput and high-content molecular and cell profiling technologies coupled with AI and predictive modeling on modern e-infrastructures can enable us to study complex phenomena in pharmacology, toxicology and metabolism.


Kathryn WhiteheadDr. Kathryn A. Whitehead, Associate Professor of Chemical Engineering and Biomedical Engineering and a Fellow of the American Institute for Medical and Biological Engineering (AIMBE), joined the Department of Chemical Engineering at Carnegie Mellon University in 2012.

The research interests of the Whitehead Lab lie at the interface of chemical engineering, molecular biology, and medicine, with ultimate goal to engineer safe and effective drug delivery systems capable of achieving therapeutic outcomes in biological models and, ultimately, in humans.


Carolina Wählby, Uppsala University Carolina Wählby is Professor of Quantitative microscopy at Uppsala University’s Department of Information Technology. After completeing her PhD in 2003, Prof. Wählby did a postdoc in genetics and pathology before joining the Broad Institute of Harvard and MIT in 2009 In 2014 she returned to Sweden and SciLifeLab.

The Wählby lab is part of SciLifeLab and the Centre for Image Analysis, Uppsala, Sweden. Research is focused on quantitative microscopy, developing digital image processing and analysis methods and tools for applications in life science. Artificial intelligence, in the form of deep learning and deep convolutional networks for analysis of microscopy data is an important part of this work.

Dr. Jimmy Ytterberg, SciLifeLab, Uppsala University (SE)

Jimmy YtterbergDr. Jimmy Ytterberg is a scientist at the SciLifeLab Drug Discovery & Development platform with focus on protein characterisation, LC-MS. Dr. Ytterberg received his PhD from Cornell University (US) before joining University of California as a Postdoctoral fellow. In 2020 Dr. Ytterberg was recruited to Uppsala University and SciLifeLab.

Dr. Jimmy Ytterberg is an experienced researcher with a demonstrated history of working in the pharmaceuticals industry. He is skilled in Bioinformatics, Liquid Chromatography-Mass Spectrometry (LC-MS), Protein Chemistry, and High-Performance Liquid Chromatography (HPLC) with a track record including 57 scientific publications.

To Scientific Program

Last modified: 2021-12-23